European School of Oncology Announces Advanced Rectal Cancer Management Course

The European School of Oncology (ESO) has launched a new Advanced Hands-On Course on Rectal Cancer Management, designed to equip oncologists with the latest surgical, radiation, and multidisciplinary treatment techniques for a disease affecting over 1.4 million people globally each year.

According to Oncodaily, the course—held in Milan, Italy, from October 15–17, 2026—focuses on emerging evidence-based strategies, including neoadjuvant therapy optimization, minimally invasive approaches, and the integration of AI-assisted diagnostics. Organizers emphasize its hands-on cadaveric dissection and simulation modules, which aim to address persistent disparities in treatment outcomes across European regions.

Rectal cancer remains a leading cause of cancer-related deaths, with survival rates varying significantly by country. A 2025 study in The Lancet Oncology found that 5-year survival in high-resource settings like Sweden (72%) exceeds that in Eastern Europe (45%), largely due to access to specialized training. The ESO course directly targets this gap by offering 40 hours of instruction from a faculty of 12 international experts, including surgeons from Memorial Sloan Kettering and the Netherlands Cancer Institute.

Why the course matters
Rectal cancer treatment has evolved rapidly in the past decade, with neoadjuvant chemoradiotherapy now standard for locally advanced disease. Yet a 2024 European Society for Medical Oncology (ESMO) audit revealed that 30% of European hospitals still lack dedicated rectal cancer multidisciplinary teams. The ESO course addresses this by combining didactic sessions with practical workshops on total mesorectal excision (TME) techniques, pelvic exenteration, and the use of intraoperative imaging.

A key focus is the role of immunotherapy in mismatch repair-deficient (dMMR) rectal cancers, where trials like NCT03770353 (KEYNOTE-168) have shown response rates of up to 60% with pembrolizumab. "The shift toward personalized treatment pathways is accelerating," said Professor Giovanni De Manzini of the ESO faculty, "but only if clinicians are trained in the latest protocols." The course includes case-based discussions on how to navigate these new options without compromising quality of life for patients.

What participants will learn
The curriculum is divided into three pillars:

• Surgical innovation: Techniques for sphincter-preserving surgery and robotic-assisted procedures, with live demonstrations from the ESO’s affiliated hospitals.
• Radiation precision: Advanced planning for intensity-modulated radiotherapy (IMRT) to reduce toxicity, based on data from the PRODIGE 23 trial.
• Multidisciplinary collaboration: How to integrate pathologists, radiologists, and oncologists in real-time treatment planning, a model now adopted by the National Comprehensive Cancer Network (NCCN) guidelines.

Registration for the course is capped at 60 attendees, with priority given to early-career oncologists from low-resource regions. Tuition covers all materials, meals, and accommodation at the ESO’s Milan campus, though travel costs remain a barrier for some applicants. Organizers are exploring scholarships in partnership with the European Society of Surgical Oncology (ESSO).

How this fits into global rectal cancer care
The ESO’s initiative aligns with the World Health Organization’s 2025–2030 cancer control targets, which call for a 20% reduction in mortality through improved training. While similar courses exist—such as the American Society of Colon and Rectal Surgeons’ annual meeting—the ESO’s program distinguishes itself by its European focus and emphasis on hands-on skills.

A 2023 survey in Annals of Surgical Oncology found that surgeons who participated in structured hands-on courses were 2.3 times more likely to adopt new techniques within 12 months. The ESO course aims to replicate this effect at scale, with follow-up assessments to track implementation rates across participant institutions.

What comes next
The ESO plans to expand the course to additional European cities by 2027, with a potential virtual component for broader accessibility. Meanwhile, the European Commission’s 2026–2030 health strategy includes funding for similar training programs, though details remain under review. For now, the Milan course serves as a model for how specialized education can bridge gaps in cancer care—provided that participants can apply what they learn in their home institutions.